VISEN PHARMA-B Repurchases 14,900 Shares for HKD 0.29 Million; Treasury Stock Rises to 140,700 Shares

Bulletin Express06-15

VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed that it bought back 14,900 ordinary shares on 15 June 2026 via on-market transactions on the Hong Kong Stock Exchange.

• Transaction details: The buy-backs were executed within a price range of HKD 19.50 to HKD 19.94 per share, at a volume-weighted average cost of HKD 19.64 per share. The aggregate consideration totalled HKD 0.29 million.

• Capital impact: Issued shares outstanding fell by 0.013 % to 113.79 million, while treasury shares increased from 125,800 to 140,700. Total issued shares remained unchanged at 113.93 million.

• Repurchase mandate utilisation: The current mandate, approved on 27 June 2025, authorises buy-backs of up to 11.39 million shares. Cumulative purchases under this authority now stand at 140,700 shares, representing 0.12 % of the shares outstanding when the mandate was granted.

• Post-repurchase restrictions: In line with Hong Kong listing rules, VISEN is subject to a moratorium on new share issues or treasury-share sales until 15 July 2026.

The board confirmed that the transaction complied with all relevant listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132906741?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132906741","market":"hk","top_or_hot":-1,"title":"VISEN PHARMA-B Repurchases 14,900 Shares for HKD 0.29 Million; Treasury Stock Rises to 140,700 Shares","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed that it bought back 14,900 ordinary shares on 15 June 2026 via on-market transactions on the Hong Kong Stock Exchange.</p>\n<p>• Transaction details: The buy-backs were executed within a price range of HKD 19.50 to HKD 19.94 per share, at a volume-weighted average cost of HKD 19.64 per share. The aggregate consideration totalled HKD 0.29 million.</p>\n<p>• Capital impact: Issued shares outstanding fell by 0.013 % to 113.79 million, while treasury shares increased from 125,800 to 140,700. Total issued shares remained unchanged at 113.93 million.</p>\n<p>• Repurchase mandate utilisation: The current mandate, approved on 27 June 2025, authorises buy-backs of up to 11.39 million shares. Cumulative purchases under this authority now stand at 140,700 shares, representing 0.12 % of the shares outstanding when the mandate was granted.</p>\n<p>• Post-repurchase restrictions: In line with Hong Kong listing rules, VISEN is subject to a moratorium on new share issues or treasury-share sales until 15 July 2026.</p>\n<p>The board confirmed that the transaction complied with all relevant listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B Repurchases 14,900 Shares for HKD 0.29 Million; Treasury Stock Rises to 140,700 Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B Repurchases 14,900 Shares for HKD 0.29 Million; Treasury Stock Rises to 140,700 Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-15 20:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed that it bought back 14,900 ordinary shares on 15 June 2026 via on-market transactions on the Hong Kong Stock Exchange.</p>\n<p>• Transaction details: The buy-backs were executed within a price range of HKD 19.50 to HKD 19.94 per share, at a volume-weighted average cost of HKD 19.64 per share. The aggregate consideration totalled HKD 0.29 million.</p>\n<p>• Capital impact: Issued shares outstanding fell by 0.013 % to 113.79 million, while treasury shares increased from 125,800 to 140,700. Total issued shares remained unchanged at 113.93 million.</p>\n<p>• Repurchase mandate utilisation: The current mandate, approved on 27 June 2025, authorises buy-backs of up to 11.39 million shares. Cumulative purchases under this authority now stand at 140,700 shares, representing 0.12 % of the shares outstanding when the mandate was granted.</p>\n<p>• Post-repurchase restrictions: In line with Hong Kong listing rules, VISEN is subject to a moratorium on new share issues or treasury-share sales until 15 July 2026.</p>\n<p>The board confirmed that the transaction complied with all relevant listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1132906741","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132906741","pubTimestamp":1781527307,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed that it bought back 14,900 ordinary shares on 15 June 2026 via on-market transactions on the Hong Kong Stock Exchange. • Transaction details: The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"VISEN PHARMA-B以29万港元回购1.49万股；库存股增至140,700股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed that it bought back 14,900 ordinary shares on 15 June 2026 via on-market transactions on the Hong Kong Stock Exchange.\n• Transaction details: The buy-backs were executed within a price range of HKD 19.50 to HKD 19.94 per share, at a volume-weighted average cost of HKD 19.64 per share. The aggregate consideration totalled HKD 0.29 million.\n• Capital impact: Issued shares outstanding fell by 0.013 % to 113.79 million, while treasury shares increased from 125,800 to 140,700. Total issued shares remained unchanged at 113.93 million.\n• Repurchase mandate utilisation: The current mandate, approved on 27 June 2025, authorises buy-backs of up to 11.39 million shares. Cumulative purchases under this authority now stand at 140,700 shares, representing 0.12 % of the shares outstanding when the mandate was granted.\n• Post-repurchase restrictions: In line with Hong Kong listing rules, VISEN is subject to a moratorium on new share issues or treasury-share sales until 15 July 2026.\nThe board confirmed that the transaction complied with all relevant listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132906741","isCrawlerRequest":true}